Product logins

Find logins to all Clarivate products below.


Bladder cancer is one of the ten most common cancers worldwide that can afflict both genders and is the 13th most common cause of death associated with cancer. A mixture of immunotherapy (BCG vaccine), chemotherapies, and surgery are currently used to treat bladder cancer. The management of early-stage bladder cancer contributes to a significant healthcare burden due to the high risk of recurrence, frequent monitoring of the disease, and high treatment costs.

Using primary research conducted with U.S. and European bladder cancer medical oncologists who have expertise treating bladder cancer, this report provides a comprehensive analysis of the competitive landscape and market opportunities for bladder cancer. This report includes an analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. Of currently approved therapies for treating bladder cancer, only valrubicin (Endo’s Valstar) and vinflunine (Pierre Fabre’s Javlor) do not yet face generic competition, even though valrubicin is no longer patent protected.

Related Market Assessment Reports

Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma | Disease Landscape & Forecast | G7 | 2024
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Current Treatment – Treatment Sequencing – Bladder Cancer and Upper Tract Urothelial Carcinoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Current Treatment – Current Treatment: Physician Insights – Bladder Cancer and Upper Tract Urothelial Carcinoma (US)
Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer and upper tract urothelial carcinoma (UTUC). Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo, once…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma | Disease Landscape & Forecast | G7 | 2023
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…